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This study showed that dihydroceramide and ceramide increased the expression of
cytochrome (CYP) P450 when HepG2 cells were exposed to 3-methylcholanthrene
(MC). Cytochrome P450s are a highly diversified set ofheme proteins responsible for
drug metabolism, blood homeostasis, cholesterol biosynthesis, and steriodogenesis.
CYPlAl, the first P450 isoform to be named, is responsible for the metabolism and
biotransformation ofpolycyclic aromatic hydrocarbons (PAH). 3-methylcholanthrene, an
extremely hazardous PAH, has been shown to induce the CYPlAl gene through the aryl
hydrocarbon receptor (AhR) pathway.
Past investigations have shown that the sphingolipid, C2-ceramide, induces
CYPlAl expression when HepG2 cells are exposed to 3-methylcholanthrene. Ceramide,
the hydrophobic moiety of all complex sphingolipids, is known to act as a second
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messenger in the cell. Unlike ceramide, dihydroceramide, the precursor of an essential
molecule needed for the formation of ceramide through the de novo pathway, has been
reported to be biologically inactive. It is hypothesized that structurally different
sphingolipids (ceramide and dihydroceramide) modulate the ability ofMC to induce
CYPlA1 expression by increasing the influx ofMC into the cell. To test this hypothesis,
CYPl A1 enzyme activity and protein amounts were assessed by the ethoxyresorufm-o-
deethylase assay and Western Blot analysis, respectively. Through confocal microscopy
it was found that the increased influx ofMC was correlated to the increased expression of
CYPlA1 in the presence of the sphingolipids when compared to MC treated cells alone.
In addition to increased influx, it was found that ceramide and dihydroceramide also
caused MC to quickly localize around the nucleus of the cells. An increased influx of
MC in cells and localization to the nucleus can lead to the increased expression of
CYPlAl for the biotransformation ofPAHs. This dual effect can potentially enhance the
chemical carcinogenesis process through increased production of the carcinogenic
metobolites of these PAHs. Sphingolipid stimulation ofCYPlAl enzyme during the
biotransformation of a PAH could then enhance the incidence of chemical
carcinogenesis.
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The Cytochrome P450 (CYP) enzymes play a vital role in the metabolism of
drugs, steroid hormones, environmental/occupational substances, and carcinogens (Coon
et al. 1992; Lu 1998; Ma and Lu 2003). CYP enzymes serve as the initial reaction in the
conversion of xenobiotics to a more polar metabolite for secretion from the body. These
enzymes use iron to oxidize lipophilic substrates to a more water-soluble compound that
can be easily excreted through urine, sweat, and tears (Ma 1995). In humans, CYPs are
found in the liver, the main organ involved in drug and toxin removal, but substantial
amounts are also found in the small intestine. CYPs are located in the microsomal
compartment of the endoplasmic reticulum where they are involved in vascular
autoregulation, the formation of cholesterol, steroids, and arachidonic acid metabolites.
There are more than seventy-four isoforms of CYP450, thirty of these isoforms are found
in humans, which are classified according to the similarities of their amino acid
sequences. Individual differences in the level of expression of the isoform CYP is
responsible for the genetic variability in CYP oxidases. There has been much speculation
about the role ofCYP enzymes and polymorphic variation in cancer initiation; because
some cancers are hormone sensitive those CYPs involved in steroid or arachidonic acid
metabolism play a crucial role in the suppression or promotion ofmalignancies (Baan et
al. 1994; Bishop 1987; Conney 1982; Ma 1995; Shimada et al. 2002).
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CYPlAl, the first CYP isoform to be named, is primarily responsible for the
metabolism ofpolycyclic aromatic hydrocarbons (PAH). CYPlAl is expressed in low
levels in extra-hepatic tissue in humans but is highly inducible in both liver and extra-
hepatic tissue. However, induction of this enzyme in human tissue exhibits large
variations. Conney, Miller, and Miller first discovered CYPlAl in 1957. Their study
revealed a substrate-inducer relationship in the induction of drug metabolizing enzymes.
Their study concluded that the substrate-induced synthesis ofCYPlAl leads to the
increased detoxification and elimination of chemicals from the body, but can be a
disadvantage because CYPlAl metabolism increases the formation of carcinogens
through metabolic activation ofPAHs (Conney, Miller, and Miller 1957). Induction of
CYPlAl by chemicals is dose dependent therefore variability in the intracellular
concentration of an inducer among individuals would result in different extents of
induction (Ma and Lu 2003). Since CYPlAl has a unique role in the metabolic
activation of carcinogens, variations of this enzyme in humans can influence an
individual’s susceptibility to chemical carcinogenesis. The oxygenation of carcinogenic
}
PAHs by CYPlAl can generate arene oxide, dioepoxide, and other electrophilic reactive
species that can adhere to DNA and cause genetic mutations leading to tumor formation
or cell toxicity (Baan et al. 1994; Conney 1982; Miller and Miller 1981). CYPlAl
induction by PAHs has been linked to several types of cancers including lung, liver,
breast, and prostate cancer (Baan et al. 1994; Bishop 1987; Coimey 1982; Shimada et al.
2002).
3-methylcholanthrene (MC), an extremely hazardous PAH, is a carcinogen in
humans, which can be found in the environment. This PAH has been shown to induce
CYPlA1 and other iso forms of the gene using the aryl hydrocarbon receptor (AhR)
pathway (Chung et al. 1994 and Quattrochi et al. 1994). Humans are exposed to MC
from a variety of sources such as tobacco smoke, automobile exhaust, industrial
processes, smoked and cooked foods (Baan et al 1994; Ma and Lu 2003). It can be
absorbed through the skin, however, the mechanism by which MC passes through the
plasma membrane is unknown. Two probable routes this carcinogen may use to gain
entry inside the cell are through facilitated transport or endocytosis. Facilitated transport
is executed by a carrier molecule that requires no energy and endocytosis is the uptake of
material into the cell by the formation of a membrane bound vesicle. Membrane
biogenesis and maintenance in eukaroyotic cells require a constant turnover ofmembrane
constituents mediated by exocytosis and endocytosis. Both of these processes use vesicle
packages composed of lipids and assorted membrane proteins that are pinched off the
membranes of one part of the cell and delivered like cargo to other subcellular
compartments. Sphingolipids contribute to the formation ofmembrane rafts and caveloe
(Brown and London 2000; Venkataraman and Futerman 2000). Lipid raft microdomains
are composed of cholesterol and sphingolipids. These compounds can compartmentalize
at the cell surface to aid in the uptake of various types ofmolecules. The uptake of
molecules (e.g. receptor clustering or toxin uptake) in lipid rafts and the formation of
endosomes can also be facilitated by transient ceramide formation.
Sphingolipids are an enigmatic class of lipids that for many years were thought to
be only structural components of the plasma membrane. These lipids were first
discovered and named by J.L.W. Thudichum in 1884 for their mysterious “sphinx-like”
properties. Today sphingolipids are known to be involved in numerous signal
transduction pathways that are essential for various biological activities that mediate cell
differentiation, cell death, cell proliferation, and calcium homeostasis. Sphingolipids can
be found in all eukaryotic cells where they are plentiful in the plasma membrane, Golgi
membrane and lysosomes. They can also be found in fiingi, as well as some prokaryotic
organisms and viruses (Merrill and Sandhoff 2002). Sphingolipids are also a significant
component ofbeef, pork, chicken, milk, butter, and cheese (Blank et al. 1992; Merrill et
al. 1997; Zeisel, Char, and Shear 1986, 1986; and Wurtman et al. 1979). These lipids are
known to be mediators of signaling pathways that regulate cell homeostasis, cell cycle
progression, and apoptosis. Sphingolipids are composed of a polar head group and two
non-polar tails. The core of all sphingolipids is the long chain amino alcohol,
sphingosine. D-e^^z/jo-sphingosine is the most common sphingolipid and is found in
very low concentrations in mammalian cells. However, sphinganine and
hydroxysphinganine are also found in mammalian cells. Sphingolipid de novo
biosynthesis starts at the endoplasmic reticulum with the condensation of serine and
palmitoyl-CoA followed by reduction of 3-ketosphinganine and the acylation of
sphinganine to dihydroceramide. Introduction of the 4, 5-trans double bond of
sphingosine into dihydroceramide is catalyzed by dihydroceramide desaturase to generate
ceramide. Ceramide is also produced through the hydrolysis of cellular sphingomyelin
catalyzed by the enzyme sphingomylinase. Mammalian cells utilize three distinct forms
of this enzyme to generate ceramide. They are differentiated as acid, neutral, and
alkaline sphingomyelinase (Gulbins and Kolesnick 2003). Only the acid and neutral
sphingomyelinase are known to be involved in signal transduction in mammalian cells
(Gulbins and Kolesnick 2003).
Ceramide is an essential sphingolipid because of is importance in the formation of
other complex sphingolipids. Ceramide constitutes the hydrophobic backbone ofall
other complex sphingolipids. Complex sphingolipids consists of sphingomyelin, an
important structural component of nerve cell membrane. Sphingomyelins are synthesized
by the transfer ofphosphorylcholine from phosphatidylcholine to ceramide catalyzed by
sphingomyelin synthase. Glycosphingolipids, or glycolipids are composed of a ceramide
backbone with a wide variety of carbohydrate groups. The four principal classes of
glycolipids are cerebrosides and gangliocides which are found in neuronal tissue,
sulfatides are found in tissues involved in sodium transport, and globosides are found in
erythrocyte plasma membranes. To generate more complex sphingolipids ceramide is
transported to the trans-Golgi network where a polar head group is attached to carbon 1.
Once synthesized, these highly bioactive lipids are sorted to other cellular compartments,
e.g. plasma membrane, where theymodify diverse enzymatic activities, transport
systems, gene expression, cell growth, differentiation, and apoptosis. Ceramide has been
recently shown to compartmentalize at the cell surface into distinct ceramide rich-
domains (Huang et al. 1999). Ceramide has been have identified in aiding in the uptake
ofbacteria or viruses (Cremesti, Goni, and Kolesnick 2002; Gulbins and Kolesnick 2003;
Shin, Gao, and Abraham 2000). These ceramide rich- rafts are capable ofmigrating
toward the center of the cell or can simply remain near the cell surface (Shin, Gao, and
Abraham 2000). Extra cellular stimuli like ultraviolet light (UV), heat, radiation, and
H2O2, can initiate the sphingomyelin cycle in the plasma membrane, increase the level of
intracellular ceramide and activate the downstream signal transduction cascade or the
formation of ceramide-enriched rafts (Fig. 1) (Liu 1999). Ceramide’s ability to act on
these various pathways is concentration dependent and cell type specific. This
sphingolipid has been shown to activate ceramide activated protein kinase (CAPK),
extracellular signal regulated kinase (ERK), and the mitogen activated/ERK (MEK)
pathway to initiate cell proliferation and inflammation while also activating tumor
necrosis factor (TNF), Jun N-terminal kinase (INK), and B cell lymphoma/leukemia-2
(BCL-2) pathway to initiate apoptosis (Fig. 1). Ceramide has been targeted as a
therapeutic agent due to its role in apoptosis. Many tumors seem to develop mechanisms
to reduce cellular ceramide concentrations, as a results many approaches to increase the





















Fig 1. Ceramide signaling pathway ( Adapted from Green 2000; Corda et al. 2001;
Kolesnick and Kronke 1998; Tcherkasowa et al. 2002; Yan, John, and Polk 2001; Zhang
et al. 1997).
Past studies have shown that the sphingolipid C2-ceramide stimulates CYPlAl
expression by MC exposure (Merrill et al. 1999). The mechanism by which this
sphingolipid modulation occurs is unknown. The hypothesis is that dihydroceramide and
ceramide increase MC’s influx inside the cells. This increased influx ofMC leads to
increased transcription of the CYPlAl gene. MC association with dihydroceramide and
ceramide could be due to their ability to form rafts at the plasma membrane. This
formation could facilitate the transport or the uptake of this carcinogen inside the cell.
Therefore, the purpose of this study was to determine ifCYPlAl induction is correlated
to membrane permeability created by the sphingolipids and to understand the mechanism
by which this carcinogen crosses the plasma membrane. The experiments conducted in
this research will identify how ceramide and dihydroceramide in conjunction with 3-
methylcholanthrene stimulate expression ofCYPlAl, a key biotransformation enzyme in
a hepatoma cell line.
CHAPTER 2
LITERATURE REVIEW
Biotransformation is the process by which animals, as well as plants, introduce
chemical changes to a molecule. Drugs, environmental pollutants, and toxins undergo
biotransformation. This biological process converts foreign chemicals, known as
xenobiotics, from lipophilic to polar compounds. These compounds can then be excreted
through urine, sweat, and tears. Drug metabolizing enzymes responsible for
biotransformation include cytochrome P450s, epoxide hydrolases, esterases, amidases,
and several transferases (Shimada et al. 2002).
Cytochrome P450
The cytochrome P450 superfamily is a highly diversified set of heme proteins
found in the endoplasmic reticulum. These enzymes can catalyze a wide variety of
reactions that include N-oxidation, sulfoxidation, epoxidation, N-, S-, 0-dealkylation,
peroxidation, deamination, desulfuration, and dehalogenation (Shimada et al. 2002).
CYP proteins require the use of iron and oxygen to metabolize a lipophilic substrate,
producing a more water-soluble product (Baan et al. 1994). CYPs are often referred to as
mixed function oxidases or monooxygenases, due to the insertion ofmolecular oxygen
into the final product (Ingelman-Sundberg 1999). The oxidation process is complex and
requires the donation of two electrons from NADPH, which serves as an electron
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donor (Fig. 2). The initial P450 mediated oxidation is referred to as Phase I
metabolism and the subsequent conjugation, not catalyzed by CYPs, is Phase II
metabolism. In / reactions a small polar group is either exposed on the toxicant or
added to the toxicant. There are three main / reactions, oxidation (substrate loses
electrons), reduction (substrate gains electrons), and hydrolysis, which introduce a water
-3 I
molecule that splits the toxicant into two fragments or smaller molecules. The Fe of the
heme moiety is the site of the catalytic reaction and the reduced state (Fe^"^) is responsible
for the strong 450 nm absorption peak in combination with carbon monoxide. The
accepted catalytic cycle begins when the substrate (RH) binds to the oxidized form of
cytochrome P450 (Fig. 2). An electron can then be transferred to the resulting enzyme-
substrate complex via a flavoprotein NADPH cytochrome P450 reductase. Once bound,
a water molecule forms a ligand to the heme iron atom. This step in the reaction causes a
change in the redox-potential of the iron from approximately -300 mV to approximately -
170 mV. A decrease in redox-potential makes the reduction of iron by the NADPH of
the cytochrome thermodynamically favorable. This step is followed by the binding of an
oxygen molecule to a separate site (RH) adjacent to the Fe ion. Oxygen then reacts
with protons from the surrounding solvent to form water, which is released leaving an
activated oxygen atom, which then may react with the substrate (ROH) molecule
resulting in a hydroxylated form of the substrate. This entire reaction cycle usually takes
between 1-10 seconds (Ohkawa and Ohkawa 1998).
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Fig. 2. Cytochrome P450 monooxygenase reaction.
There are seventeen families ofhuman CYPs identified and they are critical for
drug metabolism, blood homeostasis, cholesterol biosynthesis, and steriodogenesis
(Ingelman-Sundberg 1999). CYP proteins are expressed at highest levels in the liver and
small intestines but are also active in the gastrointestinal tract, kidney, lungs, liver and
skin. Within the cell they are located in the endoplasmic reticulum and mitochondrial
membrane (Adesnick and Atchinson 1986). Until just recently, CYPlAl was believed to
be the only enzyme that catalyzes activation of pro-carcinogenic PAHs. Now, CYP2 and
CYPS have also been identified as major enzymes in the metabolism ofpotential pro-
carcinogenic xenobiotics, which includes PAHs, nitro-polyhydrocarbons, aryl, and
heterocyclic arylamines (Coon et al.l992; Lu 1998).
PolycyclicAromatic Hydrocarbons
Many chemical carcinogens in the environment are chemically inert and require
metabolic activation by CYPs to become more reactive metabolites that induce
carcinogenicity (Conney 1982; Miller and Miller 1981). Polycyclic aromatic
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hydrocarbons (PAH) are a class of structurally similar chemical compounds
characterized by the presence of fused aromatic rings (Fig. 3). These extremely
hazardous compounds can be found in the environment as pollutants of air, water, and
soil. Polycyclic aromatic hydrocarbons are typically formed during the incomplete
burning of organic material ranging from coal, to gasoline, to garbage. Excessive
broiling ofmeat and burning of tobacco are other sources ofPAH generation (Baan et al.
1994). Occupational groups exposed to PAH include coke-oven workers, roofers,
chimneysweepers, and asphalt-road builders (Baan et al. 1994). Non-occupational
exposure to PAH can be found among smokers and in populations living in heavily
industrialized areas (Baan et al. 1994). Continuous exposure to these hazardous
compounds has been linked to various types ofhuman cancer (e.g., lung, breast, liver,
colon, bladder, and prostate cancer) (Baan et al. 1994; Miller and Miller 1981; Shimada
et al. 2002). Some pro-carcinogenic PAHs include 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), MC, and benzo [a] pyrene (BP). These compounds are chemically inert and are
not water-soluble. Upon entering the body they are converted by various metabolizing
enzymes like CYPlAl into more excretable products (Chung and Bresnick 1997;
Quattrochi, Vu, and Tukey 1994). However, CYP enzymes can convert these inert
compounds to epoxide intermediates, which are then converted by epoxide hydrolase to
the ultimate carcinogens, diol-epoxides (Baan et al. 1994; Bishop 1987; Conney 1982;
Shimada et al. 2002). These species can then bind to DNA to form adduets or DNA
lesions with the consequent development ofmalignancy (Baan et al. 1994; Conney 1982).
The formation of these adducts is considered to be the initial event in chemical
carcinogenesis (Baan et al. 1994; Bishop 1987; Conney 1982; Shimada et al. 2002).
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Fig. 3. 3-Methylcholanthrene, an example of a PAH
CYPlAl Induction Pathway
Once a PAH enters the cell, it binds to the aryl hydrocarbon receptor (Fig. 4).
The AhR functions as a ligand-activated receptor, whose biological function has been
implicated in the development of the liver and immune system, vascular remodeling, cell
cycle regulation, cell differentiation, and in the induction ofCYPlAl (Gu et al. 2000;
Femandez-Salguero et al. 1995; Ma and Whitlock 1995; Ma and Anthony 2003; Lahvis
et al. 2000). Many of the ligands known to bind AhR are toxic, even carcinogenic.
However, there are several natural ligands that include tryptophan, 7-keto-cholesterol,
and resveratrol, a dietary constituent found in the plant Vitis vinifera and labrusca grapes
(Casper et al. 1999; Bjeldanes et al. 1991; Savouret et al. 2001; Riddick et al. 2003). This
intracellular receptor is associated with a chaperone complex composed ofheat shock
protein (hsp) 90 and aryl interacting protein (AIP) that beeomes activated upon ligand
binding (Berg and Pongratz 2002; Carver and Bradford 1997; Ma and Whitloek 1997;
Nair et al. 1997). The localization of the AhR-hsp90-AIP complex has been somewhat
controversial. There have been studies that report that the complex is equally distributed
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in the cytoplasm and the nucleus before activation by an external ligand (Berg and
Pongratz 2001; Berg and Pongratz 2002). Others have reported that the receptor complex
resides only in the cytoplasm until activated (Bell and Poland 2000). Once activated by
an external ligand the hsp90/AhR/AIP complex translocates to the nucleus. Once in the
nucleus the complex must dissociate before the AhR-ligand complex trimerizes with the
arylhydrocarbon receptor translocator (Amt) (Bell and Poland 2000; Ma 2001). Together
both receptors bind the xenobiotic responsive element (XRE) region of the CYP gene to
initiate transcription (Bell and Poland 2000; Gu et al. 2000; Ma 2001; Kazlaukus,
Poellinger, Pongratz 2000). There is evidence that PAHs may also use an AhR-
independent pathway to induce CYPlAl activity. Studies using AhR null mice and
AhR-deficient mouse hepatoma cells show both AhR-dependent and independent
pathways are essential in the induction of CYPlAl (Kondraganti et al. 2003), though
DNA adduct levels were significantly increased in the wild type mice (AhR +/+) rather
than in knockout mice that lacked the AhR (-/-) (Kondraganti et al. 2003).
AHR
Fig. 4. Metabolism of an external ligand by CYP isoforms using the AhR-pathway.
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Previous studies in our laboratory have shown that sphingolipids can assist
PAHs like MC in the induction ofCYPlA1 in human liver carcinoma cells (HepG2). In
HepG2 cells treated with MC and exogenous C2-ceramide, CYPlAl activity and protein
amount were significantly increased when compared to cells treated with PAH alone {in
preparation). However, when HepG2 cells were treated with ISPl (a sphingolipid
synthesis inhibitor), and a PAH, CYPlAl activity and protein amount decreased
significantly from that seen with the PAH alone (Merrill et al. 1999). The involvement of
sphingolipids in the induction ofCYPlAl demonstrates an active role for the lipids in the
biotransformation process and perhaps subsequently, in environmental carcinogenesis.
Sphingolipids
Sphingolipids are widely distributed in animal tissues. The kidney has primarily
served as an important tissue for the study of sphingolipids, however, the liver and
lactating mammary glands have also been shown to contain significant amounts of
sphingolipids (Shayman 2000). These lipids are primarily found in the plasma membrane
in animal cells, but are more widely distributed in plants and lower eukaryotes. All
sphingolipids consists of long-chain sphingoid bases linked to a fatty acid by an amide
bond (Shayman 2000; Smith and Merrill 2002). Their functions involve interactions that
occur on the cell surface, since much of the sphingolipids reside in the external leaflet of
the plasma membrane. Sphingolipids have been shown to regulate growth factor
receptors, cell adhesion, and cell-cell communication (Cremesti, Goni, and Kolesnick
2002; Shayman 2000). The most common sphingolipids contain long-chain bases (C-18
and C-20) referred to as sphingosines (Cremesti, Goni, and Kolesnick 2002; Karlsson
1970; Liu, Kleine, and Hebert 1999; Shayman 2000). These bases contain a C4-C5
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double bond in the trans T>-erythro conformation. Dihydrosphingosines C-18 and C-
20 are the next most common long-chain bases that lack the double bond in the C4-C5
position (Cremesti, Goni, and Kolesnick 2002; Karlsson 1970; Shayman 2000).
Ceramide Biosynthesis
The sphingolipid ceramide, a sphingosine-based lipid second messenger, is
known to be involved in the regulation of several cellular events such as cell
differentiation, vasorelaxation, apoptosis, cell stress, and heat shock responses (Liu and
Anderson 1995; Shayman et al. 2000). Structurally, ceramides are composed of a fatty
acid chain of varied length bound through an amide linkage to the amino group of the
sphingoid base (Fig. 5). The fatty acid chain length of these lipids can vary from 2-28
carbons (Cremesti, Goni, and Kolesnick 2002). Long chain naturally occurring
ceramides (and dihydroceramides, a direct precursor of ceramide), are the most abundant
sphingolipids in mammalian cells (Cremesti, Goni, and Kolesnick 2002; Karlsson 1970;
Shayman 2000). However, dihydroceramides have been reported to have little to no
biological effect when compared to ceramides. Studies using C2-dihydroceramide show
that this sphingolipid had little to no biological effect in channel formation when
compared to C2-ceramide (Siskind, Kolesnick, and Colmnbini 2002). Others have shown
that dihydroceramides were limited in channel formation when compared to C2- and






Fig. 5. General structure of ceramide
Ceramide constitutes the hydrophobic backbone of all the complex sphingolipids,
which includes sphingomyelin, glucosylceramide, galactosylceramide, and sphingosine.
Sphingolipid metabolism is regulated by several factors, which include the control of
ceramide de novo synthesis, recycling ofother sphingolipids, the turnover of
sphingolipids for cell signaling and degradation (Merrill and Sandhoff 2002). Ceramide
generation through a de novo synthesis pathway is catalyzed by ceramide synthase or
through hydrolysis of cellular sphingomyelin via an acid or neutral sphingomyelinase.
De novo synthesis of ceramide occurs at the cytosolic face of the endoplasmic reticulum,
starting with the condensation of serine and palmitoyl-CoA into sphinganine. The rapid
production of ceramide from sphingomyelin can be triggered by interleukins 1 and 4,
tumor necrosis factor, platelet derived growth factor, interferon gamma, H2O2, ultraviolet
light, radiation, and vitamin D3. Depending on the signal, ceramide is rapidly produced
and exported to the Golgi apparatus as the precursor for the synthesis of other complex
sphingolipids. Once ceramide is exported to the Golgi it can initiate the production of
sphingosine, which inhibits protein kinase C or sphingosine -1-phosphate, which
regulates mitogenesis and calcium mobilization. Ceramide production can also lead to
the formation of ceramide 1-phosphate, which is involved in membrane fusion or more
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complex sphingolipids like glucosylceramide and galactosylceramide that are
involved in cell-cell communication, cell-matrix receptors, and regulators of receptor
kinases, and phospholipases.
Ceramide has been shown to induce pore formation during apoptosis. Pore
formation studies revealed that C6-ceramide increased membrane permeability that
resulted in a high solute efflux (Montes et al. 2002). Other membrane studies have
demonstrated that long chain C16-ceramide and short chain C2-ceramide formed large
stable pores in the plasma membrane (Siskind and Columbini 2000). SDS-PAGE
analysis showed that ceramides (Cl 6 and C2) allowed release ofmitochondrial
intermembrane space proteins up to approximately 60 kDa (Siskind and Columbini
2000).
There is growing evidence that ceramide-rich regions within membranes may
constitute important signaling microdomains (Cremesti, Goni, and Kolesnick 2002;
Blitterswijk et al. 2003; Goni et. al 2005). Typically, sphingomyelin interacts very
tightly with cholesterol through hydrogen bonding between the C-3 hydroxyl group of
cholesterol and the sphingosine moiety of sphingomyelin (Blitterswijk et al. 2003;
Dobrowsky 2000; Holopainen, Subramanian, and Kinnunen 1998). This interaction
serves as the basis for raft formation. Ceramides have a very poor affinity for cholesterol
and tend to separate into exclusive ceramide-enriched microdomains (Blitterswijk et al.
2003; Dobrowsky 2000). Lipid rafts are pleomorphic membrane structures that are
resistant to nonionic detergents and are highly enriched in cholesterol, glycolipids, and
the specific protein caveolin-1 (Shin, Gao, and Abraham 2000). These rafts participate in
the transcytosis ofmacromolecules across capillary endothelial cells (Shin, Gao, and
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Abraham 2000). They also function as transmembrane signaling molecules that may
migrate toward the center of the cell or remain near the cell surface (Shin, Gao, and
Abraham 2000). Lipid rafts as well as ceramide microdomains are capable of spatially
segregating sphingomyelin on the cell surface into a compartment that is responsive to
one type of stimulus by an external ligand, (e.g., receptors and toxins) (Blitterswijk et. al
2003; Dobrowsky 2000; Holopainen, Subramanian, and Kinnunen 1998). This ensures
that the signal will only go to a location in the cell where it can act on a specific pathway.
However, cells that use ceramide formore than one signaling activity must have multiple
pools of sphingomyeUn (Blitterswijk 2003; Dobrowsky 2000). Hydrolysis of
sphingomyelin and ceramide production at the plasma membrane may lead to the ATP-
independent formation of ceramide-enriched microdomains that, upon ligand binding,
become sealed vesicles that migrate further inside the cell or stay docked at the plasma
membrane (Blitterswijk et. al 2003; Dobrowsky 2000). This could serve to concentrate
receptors at the membrane or to enhance or prevent cross-talk interactions between
sphingolipid signaling and other signaling pathways (Blitterswijk et. al 2003; Dobrowsky
2000). A number of receptors critical for initiating signal cascades are localized within
these microdomains that become sealed vesicles (Dobrowsky 2000; Moorthy, Chen, and
Randerath 1993).
The present investigation is concerned with ceramide and dihydroceramide’s
stimulation ofCYPlAl expression in the presence ofMC. The stimulation of this
enzyme by these sphingolipids leads to an increased amount of the hydrophobic




Cell growth and treatments: HepG2 cells were grown until semi-confluent at 37 °C in
Dulbecco’s modified eagle mediem (DMEM) containing 10% fetal calf serum (FBS)
cosmic serum. Cell viability was assessed using 0.4% trypan blue. Once counted, cells
were split (typically 10^ cells /plate) then transferred to 60 x 15 mm plates and fed every
other day. Old medium was replaced with fresh DMEM without FBS or cells were pre¬
treated with 10 pM methyl-p-cylcodextrin (mP), a lipid raft inhibitor for 24 hours. For
the dose curve, cells were treated with various concentrations of 3-methylcholanthrene,
C2-ceramide, or C2-dihydroceramide (0-10 pM). Cells were then treated with 5 pM MC
alone or with either 5 pM MC + 5 pM C2 - or C6- ceramide, 5 pM C2 - or C6 -ceramide
alone or left untreated fori 8 hours. After 18 hours, plates were washed twice with ice
cold phosphate buffered saline (PBS) and 1.2 mL of 0.1 M NaHP04 (pH 7.6) was added
to plates. Cells were scraped from the plates using a rubber policeman then dounce
homogenized ~ 20 times. The homogenates were stored at -70°C.
Protein Assay; Total protein concentration of each homogenate was determined using
the Bradford assay (BIO-RAD, Hercules, CA) on 96-well microtiter plates with bovine




Enzyme Assay: CYPlA1 enzyme activity of the homogenates was measured by the
ethoxyresorufm-o-deethylase assay (EROD) (Burke and Mayer 1974). The reaction
mixture contained 0.1 M NaHP04,10 P-NADPH, 0.5 |j.M ethoxyresorufin, and 100
|j,g ofhomogenate protein. Samples were incubated in a 37 °C water bath for 10 minutes
then immediately transferred to ice where the reaction was stopped with ice-cold acetone.
The samples were centrifuged for 5 minutes at 12,000 rpm. The supernatant was read on
a spectrofluorometer in triplicates at an excitation wavelength of 580 nm and emission
wavelength of 600 nm to determine the amount of resorufin produced. The specific
activity for each treatment group was compared and graphed in SigmaPlot 5.0 (SPSS
Inc.). Analysis of variance statistical test was used to determine if there was a significant
difference in CYPlA1 specific activity in the different samples.
CYPlAl Protein Analysis
Cell Growth and Treatments: HepG2 cells were grown until semi-confluent at 37 °C in
DMEM containing 10% FBS. Cells were then treated with 5jj,M MC alone or with either
5 pM MC + 5 pM C2 - or C6- ceramide, 5 pM C2 - or C6 -ceramide alone or left
untreated for 18 hours. After 18 hours plates were washed twice with PBS. Cells were
lysed with cold immunoprecipitation buffer (150 mM NaCl, 10 mM Tris-HCL (pH 7.4),
1 mM EDTA, 1 mM EGTA, 0.2 mM sodium orthovanadate, 0.2 mM PMSF, 1% Triton
X, 0.5% NP-40). Lysates were agitated for 30 minutes at 4 °C then sonicated 5 seconds
(twice). Samples were spun down for 10 minutes at 3220 rpm (Harlow et. al 1998).
Protein Assay: Total protein concentrations of each homogenate were determined using
the Bradford assay on 96-well microtiter plates with BSA as the standard. Samples were
read on Spectramax 340 PC at 595 nm in duplicate.
Western Blot Analysis: Aliquots of crude cell lysates from each treatment group were
subjected to electrophoresis in a denaturing Tris-HCl polyacrylamide gel. The resolving
gel was 10% acrylamiderbisacrylamide and the stacking gel was 5%
acrylamide:bisacrylamide. The gel ran at a constant current of 120 millivolts for 2 hours
at 4 °C. The gel was transferred to a PVDF membrane (Millipore, Bedford, MA) for 1
hour at 10 volts using a Trans-Blot semi-dry transfer cell (BIO-RAD, Hercules, CA).
After this process, the membrane was immersed in blocking buffer and blocked overnight
at 4 °C. The membrane was submerged in an anti-rabbit CYPlA1 primary antibody
(1:10,000) (Santa Cruz Biotechnology, CA) overnight. The membrane was washed three
times (15 minutes each) with PBS-T. The membrane was then incubated with the
secondary antibody, horseradish peroxidase conjugated anti-rabbit IgG, at 1:1000 dilution
(Sigma, St. Louis, MO) in 5% fatty acid-free BSA for 1 hour at room temperature on an
orbital shaker. The membrane was washed with PBS-T three times for 10 minutes each.
The membrane was then developed by film exposure to detect the chemiluminescent
substrate (Amersham ECL plus kit, Piscataway NJ). Densitometric analysis was used to
calculate the relative amount ofprotein present in each lane.
Confocal Microscopy
Fluorescent Scans: MC was dissolved in dimethyl sulfoxide (DMSO) to yield a final
concentration of 5 pM. The mixture was then scanned on a PTI spectroflurometer to
determine maximal emission and excitation wavelengths.
Confocal Microscopy: HepG2 cells were plated (3x10^^ cells/mL) on a four-well glass
slide (Nunc Lab Tech II) and incubated overnight at 37 °C. Four hours prior to treatment,
cells were fed DMEM without FBS then pre-treated with 10 pM mp for one hour. Cells
were then treated with 5 |a.M MC, 5 |a,M C6 - ceramide or 100 nM C6-4, 7-9
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nitrobenzoflirazan (NDB)-ceramide alone, or 5 MC+ 5 |j,M C6 - or 5 p-M MC+lOO
nM C6- NDB-ceramide, or left untreated for 1 minute or 5 min. After treatments cells
were fixed with 3% formaldehyde for 15 minutes. Slides were then stained with SYTOX
green (nucleus), and Alexa Fluor 568 phalloidin (cytoskeleton) for 10 - 45 minutes. No
stain was used for MC. MC is autofluorescent at an excitation wavelength of 365 nm and
an emission wavelength of410 nm. Slides were mounted using Fluoromount-G
(Biotechnology Associates, Inc.) and observed under a Zeiss LSM 510 confocal
microscope.
MetaMorph Computer Analysis: Non-parametric analysis was used to quantitate the
amount ofMC molecules that permeate the cells in the presence and absence of the
exogenously added sphingolipids. The MetaMorph (Universal Imaging Corp.,




3-Methylcholanthrene andSphingolipid’s Effect on CYPlAl EnzymeActivity and
Protein Amounts
Figure 6 shows that in the presence ofMC alone there was a continual increase in
CYPlAl activity as the concentration ofMC increased from 2.5 pM to 5 pM. However,
there was a slight decrease in activity at 10 pM. Thus, it was determined that 5 pM MC
yield the maximum CYPlAl activity under the experimental conditions used. When
dose response studies were done with varying concentrations of C2-ceramide in the
presence of 5 pM MC there was a steady increase from 0 to 5 pM (Fig. 7). However, at
10 pM C2-ceramide, the amount ofCYPlAl activity drastically decreased. In the
presence ofvarying concentrations of dC2-ceramide CYPlAl activity increased slightly
at 2.5 pM as compared to no dC2-ceramide. Though CYPlAl activity increased
gradually at 5 pM and 10 pM, it is not significantly different from that at 2.5 pM. It was
decided that 5 pM ceramide or dC2-ceramide would he used in all subsequent studies.
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Fig. 6. Dose-response curve of CYPlA1 enzjnne activity in the presence ofMC. HepG2






Fig. 7. Dose-response curve ofCYPlAl enzyme activity in the presence ofMC and
structurally different sphingolipids. HepG2 cells were treated with 5 pM MC and various
concentrations ofC2-ceramide or dC2-dihydroceramide alone or in combination for 18
hours (n=3).
Based on the results from both dose-response curves 5 pM MC and 5 pM C2-
ceramide or C2-dihydroceramide would be a sufficient concentration to stimulate the
production of the CYPlAl enzyme. Once a significant concentration ofboth compounds
was determined, HepG2 cells were treated with 5 pM C2-or C6-ceramide and 5 pM C2-
or C6- dihydroceramide alone or in combination with 5 pM 3-methylcholanthrene to
determine CYPlAl specific activity (Figs. 8 and 9). The EROD analysis showed that
MC increased CYPlAl enzyme activitybyl5-fold when compared to untreated HepG2
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cells. In the presenee ofC2-ceramide and MC there was a significant 3-fold increase in
CYPlA1 activity compared to MC treatment alone (Fig. 8) (p<0.05). When C2-
dihydroeeramide was used in combination with MC again there was an approximate 3-
fold increase in enzyme activity compared to MC treated cells (Fig. 8) (p<0.05). HepG2
cells treated with both C6-ceramide and C6-dihydroceramide in concert with MC show a
significant 3-4-fold increase in enzyme activity compared to MC treatment alone (Fig. 9)
(p<0.01). However, there was no real significant difference between the four structurally
different sphingolipids.
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Fig. 8. Modulation ofCYPlA1 enzyme activity by MC, C2-ceramide, and C2-
dihydroceramide treatments. HepG2 cells were treated with 5 pM MC, 5 pM C2-
ceramide, 5 pM C2-dihydroceramide alone, in combination or left untreated (UN) for 18
hours. **Significantly different from MC treatments n=3 (p<0.05).
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Fig. 9. Modulation ofCYPlAl enzyme activity by MC, C6-ceramide, and C6-
dihydroceramide treatments. HepG2 cells were treated with 5 pM MC, 5 pM C6-
ceramide, 5 pM C6-dihydroceramide alone, in combination, or left untreated (UN) for 18
hours. *Significantly different from MC treatments n=3 (p<0.01).
To determine if these sphingolipids formed rafts or mierodomains to increase
the influx ofMC and therefore the transcription ofCYPlAl, HepG2 cells were pre-
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treated with mp a lipid raft inhibitor (Fig. 10). HepG2 cells pre-treated with mp then
treated with MC showed no significant difference in CYPlAl enzyme activity when
compared to MC treated cells not pre-treated with mp. As usual there was a 3-fold
increase in enzyme activity when HepG2 cells were treated with MC and C2-ceramide
(p< 0.01). However, CYPlAl enzyme activity was completely suppressed when HepG2
cells were pre-treated with mP then treated with MC and C2-ceramide. There was no
significant difference between HepG2 cells pre-treated with mp then MC compared to
cells treated with only MC.
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Fig. 10. Modulation ofCYPlAl enzyme activity by methyl-P-cylcodextrin treatments.
HepG2 cells were pre-treated with or without mP for 24 hours then treated with 5 pM
MC, 5 pM C2-ceramide alone, in combination, or left untreated (UN) for 18 hours.
*Significantly different from MC treatments n=3 (p<0.01).
Western blot analysis, a more sensitive assay, was used to confirm ceramide and
dihydroceramide’s ability to stimulate CYPlA1 protein amounts in the presence ofMC
(Fig.l 1). HepG2 cells treated with MC and C2- or C2-dihydroceramide show a 2-to-3-
fold increase in CYPlAl protein amounts when compared to MC treated cells. C6-
ceramide and C6-dihydroceramide used in combination with MC showed a 6-to-7-fold
increase in CYPlAl protein amounts (Fig. 11).
-58kd-
Fig. 11. Modulation ofCYPlAl protein amounts by MC, C2- or C6-ceramide, C2- or
C6-dihydroceramide treatments. {Top) Recombinant CYPlAl protein (R), HepG2 cells
were left untreated (lane 1) or treated with 5 pM MC (lane 2), 5 pM C2-ceramide (lane
3), 5 pM MC+C2-ceramide (lane 4) 5 pM C2-dihydroceramide (lanes 5), 5 pM MC+C2-
dihydroceramide (lane 6), 5 pM C6-ceramide (lane 7), 5 pM MC+C6-ceramide (lane 8),
5 pM C6-dihydroceramide (lane 9) or 5 pM MC+C6-dihydroceramide (lane 10).
CYPlAl protein amounts were assessed by Western Blot analysis, (Bottom)
densitometry readings were used to quantify relative protein amounts.
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Influx of3-Methylcholanthrene into HepG2 Cells Before andAfter Sphingolipid
Treatment
Confocal microscopy could be used for visualizing and monitoring the
localization ofMC influx before and after sphingolipid treatments. First, it had to be
established that MC could be used for confocal microscopy. When fluorescence
excitation spectra were measured for MC in DMSO (solvent), the spectra showed that
MC has an emission range of 399 nm - 450 nm and an excitation range of299 nm - 401
nm (Fig. 12). Once it was established that MC could be seen in the blue range of the
visible spectrum cellular influx of the carcinogen in HepG2 cells at one and five minutes
was observed. In as little as one minute there was a substantial amount ofMC inside the
cells and MC was evenly dispersed throughout the cell (Figs. 13 and 14). Surprisingly, at
five minutes there was a drastic increase in the amount of the carcinogen inside the cell
compared to one minute treatments (Figs. 15 and 16). MetaMorph software analysis was
used to determine the relative amounts ofMC entering the cell and it confirmed that
between one and five minutes there was an increase in the amount ofMC well inside the
cells (Table 1, column 1). Next MC influx in HepG2 cells after sphingolipid treatment
was determined. In the presence ofC6-ceramide, MC had begun to localize around the
nucleus (Figs. 17 and 18). The same tight localization was seen in the presence ofC6-
dihydroceramide (Figs. 19 and 20). MetaMorph analysis verified that there was an
increase in the amount ofMC entering the cells in the presence ofboth sphingolipids
compared to cells treated with only MC for one minute, although MC influx in the




Fig: 12. Flourescent Scan ofMC dissolved in DMSO.
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Fig. 13. MC cellular influx into HepG2 cells after one minute. HepG2 cells were treated
with MC for one minute. The cyotskeleton is seen in red, the nucleus is seen in green and
MC is seen in blue (40 x magnification).
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Fig. 14. MC cellular influx into HepG2 cells after one minute. HepG2 cell were treated
with MC for one minute. MC is seen in blue, there is no cytoskeletol or nuclear staining
(40 X magnification).
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Fig. 15. MC cellular influx into HepG2 cells after five minutes. HepG2 cells were
treated with MC for five minutes. The cytoskeleton is seen in red, nucleus is seen in
green and MC is seen in blue (40 x magnification).
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Fig. 16. MC cellular influx into HepG2 cells after five minutes. HepG2 cells were
treated with MC for five minutes. MC is seen in blue, there is no cytoskeletol or nuclear
staining, (40 x magnification).
Table 1:
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132±2.1 80 ± 1.9
MC+Cb-dihydroceramide
1 minute
176 ±4.5 118.5 ±0.9
Values represent 3 >n, -S.D.
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Fig. 17. MC cellular influx in HepG2 cells treated with C6-ceramide. HepG2 cells were
treated with MC and C6-ceramide for one minute. The cytoskeleton is seen in red, MC is
seen in blue and there is no nuclear staining (40 x magnification).
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Fig. 18. MC cellular influx in HepG2 cells treated with C6-ceramide. HepG2 cells were
treated with MC and C6-ceraniide for one minute. MC is seen in blue, there is no
cytoskeletol or nuclear staining (40 x magnification).
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Fig. 19. MC cellular influx in HepG2 cells treated with C6-dihydroceramide. HepG2
cells were treated with MC and C6-dihydroceramide for one minute. The cytoskeleton is
seen in red, nucleus is seen in green, and MC is seen in blue (40 x magnification).
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Fig. 20. MC cellular influx in HepG2 cells treated with C6-dihydroceramide. HepG2
cells were treated with MC and C6-dihydroceramide for one minute. MC is seen in blue,
there is no cytoskeletol or nuclear staining (40 x magnification).
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To monitor sphingolipid and MC’s localization, C6-NDB-ceramide, a
fluorescent analog, was used. HepG2 cells treated with MC and the fluorescent analog
revealed that both compounds localized around the peri-nuclear region (Fig. 21 and 22).
When C6-NDB and MC localization was visualized separately with no cytoskeletol or
nuclear staining, treatments revealed that the compounds co-localize in the same area
(Figs. 23 and 24). These results suggest that MC may be interacting or associating with
the sphingolipids.
Fig. 21. MC and C6-NDB-Ceramide localization in HepG2 cells. HepG2 cells were
treated with MC and C6-NDB-ceramide for one minute. C6-NDB-ceramide is seen in
green and the cytoskeleton is seen in red, MC is seen in blue, there is no nuclear staining
(40 X magnification). Arrows denote MC and C6-NDB-ceramide co- localization.
44
Fig. 22. MC and C6-NDB-Ceramide localization in HepG2 cells. HepG2 cells were
treated with MC and C6-NDB-ceramide for one minute. C6-NDB-ceramide is seen in
green and MC is seen in blue, there is no cytoskeletol or nuclear staining (40 x
magnification). Arrows denote MC and C6-NDB-ceramide co-localization.
45
Fig. 23. C6-NDB-Ceramide localization in HepG2 cells. HepG2 cells were treated with
MC and C6-NDB-ceramide for one minute. C6-NDB-ceramide is seen in green, there is
no cytoskeletol, MC or nuclear staining (40 x magnification). Arrows denote C6-NDB-
ceramide localization.
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Fig. 24. MC localization in HepG2 cells. HepG2 cells were treated with MC and C6-
NDB-ceramide for one minute. MC is seen in blue, there is no cytoskeletol, nuclear, or
C6-NDB ceramide staining (40 x magnification). Arrows denote MC localization.
Methyl-P-cyclodextrin was used to determine if there would be an increase or
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reduction in the influx MC. MC’s cellular influx was reduced in the presence of the
inhibitor at one minute (Figs. 25 and 26). There was a drastic reduction in MC’s influx at
five minutes in the presence of the inhibitor (Fig 27 and 28). MetaMorph confirmed this
reduction at both time intervals (Table 1, column 2). When HepG2 cells were pre-treated
with mP then treated with MC and C6-ceramide the influx of the carcinogen reduced
when compared to MC and mp treated cells (Figs. 29 and 30). The same reduction is
seen with C6-dihydroceramide and mP treated cells. Not only was the amount ofMC
entering the cell reduced in the presence of the sphingolipids, MC was no longer
localized to the peri-nuclear region of the cells (Figs. 31 and 32). MetaMorph analysis
revealed that when HepG2 cells were pre-treated with mp, there was a reduction in the
amount ofMC entering the cells both in the presence and absence of the sphingolipids
when compared to MC and sphingolipid treated cells (Table 1, column 2).
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Fig. 25. MC cellular influx into HepG2 cells at one minute after mP pre-treatments.
HepG2 cells were pre-treated with mP for one hour then treated with MC for one minute.
The cytoskeleton is seen in red and MC is seen in blue, there is no nuclear staining (40 x
magnification).
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Fig. 26. MC cellular influx into HepG2 cells at one minute after m(3 pre-treatments.
HepG2 cells were pre-treated with mp for one hour then treated with MC for one minute.
MC is seen in blue, there is no cytoskeletol or nuclear staining (40 x magnification).
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Fig. 27. MC cellular influx into HepG2 cells at five minutes after mp pre-treatments.
HepG2 cells were pre-treated with mP for one hour then treated with MC for five
minutes. The cytoskeleton is seen in red, the nucleus is seen in green and MC is seen in
blue (40 X magnification).
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Fig. 28. MC cellular influx into HepG2 cells at five minutes after mp pre-treatments.
HepG2 cells were pre-treated with mP for one hour then treated with MC for five
minutes. MC is seen in blue, there is no cytoskeletol or nuclear staining (40 x
magnification).
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Fig. 29. MC cellular influx into HepG2 cells after C6-ceramide and mp pre-treatments.
HepG2 cells were pre-treated with mP for one hour then treated with MC and C6-
ceramide for one minute. The cytoskeleton is seen in red and MC is seen in blue, there is
no nuclear staining (40 x magnification).
53
Fig. 30. MC cellular influx into HepG2 cells after C6-ceramide and mp pre-treatments.
HepG2 cells were pre-treated with mP for one hour then treated with MC and C6-
ceramide for one minute. The MC is seen in blue and the nucleus is seen in green, there
is no cytoskeletol staining (40 x magnification).
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Fig. 31. MC cellular influx into HepG2 cells after C6-dihydroceraniide and mp pre¬
treatments. HepG2 cells were pre-treated with mp for one hour then treated with MC and
C6-dihydroceramide for one minute. The cytoskeleton is seen in red and MC is seen in
blue. There is no nuclear staining (40 x magnification).
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Fig. 32. MC cellular influx into HepG2 cells after C6-dihydroceramide and mp pre¬
treatments. HepG2 cells were pre-treated with mP for one hour then treated with MC and
C6-dihydroceramide for one minute. MC is seen in blue, there is no cytoskeletol or
nuclear staining (40 x magnification).
CHAPTER 5
DISCUSSION
The overall objective of this research was to identify how dihydroceramide and
ceramide increase CYPlA1 induction in HepG2 cells exposed to MC. The results of this
study indicate this stimulation is due to the increased influx of the carcinogen into HepG2
cells in the presence of the sphingolipids. Results from the dose-response curve were
used to determine an appropriate concentration needed to produce a significant level of
CYPl A1 enzyme in the presence of the MC and the structurally different sphingolipids.
Both dose response curves specifically show that 5 pM MC, 5 pM ceramide, and 5 pM
dihydroceramide are sufficient for a significant increase in CYPlAl expression (Figs. 6
and 7). CYPlAl enzyme production differed when MC is used in conjunction with
ceramide compared to dihydroceramide, however both sphingolipids do increase
CYPlAl expression when cells are exposed to MC.
In the presence of 5 pM C2-ceramide or 5 pM C2-dihydroceramide in
combination with 5pM MC there is a significant 2-to-3-fold increase, respectively, in
CYPlAl enzyme activity when compared to MC treated cells (Fig. 8). There is also a
significant 2-3-fold increase in CYPlAl enzyme activity when 5 pM C6-ceramide and
C6-dihydroceramide are used in concert with 5 pM MC when compared to MC treated
cells alone (Fig. 9). Western blot analysis confirmed the EROD data. Both 5 pM C2-
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ceramide and 5 C2-dihydroceramide in combination with 5 jiM MC significantly
increased CYPlA1 protein amounts when compared to HepG2 cells treated with MC
alone (Fig. 11). The same increase is seen in CYPlAl protein amounts when 5 pM C6-
ceramide or 5 pM C6-dihydroceramide were used in combination with 5 pM MC (Fig.
11). The results obtained from both EROD and western blot substantiates that CYPlAl
expression in response to MC induction is significantly increased by ceramide as well as
dihydroceramide.
Previous studies in our laboratory found that HepG2 cells treated with MC and
C2-ceramide showed no significant change in AhR mRNA, Amt mRNA, or the AhR-
Amt-MC triplex association in the nucleus {in preparation). Preliminary studies have
also shown that treatment with MC and C2-ceramide significantly increased
sphingomyelinase (a critical enzyme involved in ceramide production through the
hydrolysis of sphingomyelin). Studies using ^[H] MC revealed that in the presence of
C2-ceramide, MC influx significantly increased in HepG2 cells {in preparation). These
observations led to the current research hypothesis that ceramide’s effect on CYPlAl
induction in the presence ofMC is due to events occurring at the plasma membrane.
To determine ifMC could be visualized for confocal microscopy fluorescent
scans were conducted, it was determined that MC could be seen in blue (Fig. 12). When
HepG2 cells were treated with MC at one or five minutes, there was an increase in the
amount of the carcinogen entering the cell (Figs. 13, 14, 15 and 16). In HepG2 cells
treated with MC and C6-ceramide or C6-dihydroceramide, the amount ofMC
substantially increased at both time intervals compared to HepG2 cells treated with only
MC (Figs. 17, 18, 19 and 20). One of the most interesting observations was that in the
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presence ofboth C6-ceramide and C6-dihydroceramide MC had localized around the
peri-nuclear region of the cell. Another interesting observation was that MC seemed to
localize in small pockets and these pockets increased in the presence of the sphingolipids.
Once it was established that there was an increase in the amount ofMC entering the cell
in the presence of the sphingolipids, C6-NDB-ceramide and MC localization was
monitored in HepG2 cells. Both compounds seemed to co-localize around the peri¬
nuclear region however, it was not determined into which cellular compartment MC was
sorted (Fig. 21, 22, 23, and 24).
To determine if inhibition of raft formation would reduce the influx ofMC,
HepG2 cells were pre-treated with methyl-P-cylcodextrin. Pre-treating cells with the
inhibitor reduced the amount ofMC entering the cell at both one and five minutes (Figs.
25 and 26). There was a greater reduction ofMC entering the cell in the presence of the
sphingolipids (Figs. 27 and 28). Not only did mP decrease the amount ofMC entering
the cells in the presence ofC6-ceramide and C6-dihydroceramide but the inhibitor
disrupted cellular localization ofMC. EROD data also confirmed CYPl A1 enzyme
activity was greatly suppressed when MC, mp, and C2-ceramide were used in
combination (Fig. 10). There was no significant difference in CYPlAl enzyme activity
when HepG2 cells were pre-treated with mP then treated with MC compared to HepG2
cells treated with MC alone. This insignificant induction ofCYPlAl enzyme activity
may be due to MC utilizing cholesterol containing lipid rafts as an alternative mechanism
of entering the cells. However, there was the usual significant enhancement ofCYPlAl
induction by MC in the presence of C2-ceramide. These results support the conclusion
that MC’s increased influx is correlated with the induction ofCYPlAl. When MC is
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allowed to enter the cell on its own, likely through diffusion given its hydrophobicity, it
can initiate the signal transduction pathway that leads to the enhanced (over basal levels)
transcriptions ofCYPlA1 protein and subsequent enhanced enzyme activity. When
MC’s transport into the cell is facilitated by ceramide, likely through the formation of
lipid rafts or microdomains the induction ofCYPlA1 increased. However, when the
transport ofMC into the cell is impeded, perhaps through inhibition of raft formation, its
ability to induce CYPlA1 is likewise seriously blocked.
There are several studies that support our conclusions. First ceramide has the
ability to form pores. It has been reported that short and long chain ceramide analogs can
form pores in the mitochondrial membrane (Siskind and Colombini 2000). However,
dihydroceramides are poor at forming channels and do not initiate apoptosis (Siskind and
Colombini 2000). It is possible that if an individual is exposed to MC, MC could trigger
the increased production of ceramide then ceramide could initiate the beginning stages of
apoptosis through a signaling cascade that involves the downstream activation ofCAPK,
cathepsin D, and serine/theronine protein phophatases PPl and PP2. However, studies
conducted by Lindner et al. 2005, showed that endothelial cells treated with 30 pM C6-
ceramide increased membrane permeability in a non-apoptotic mechanism. Also results
from the dose-response curve presented in this study indicate that CYPlAl expression is
high when lower concentrations ofMC and the structurally different sphingolipids were
used (Figs. 6 and 7). The conclusions drawn from Lindner’s study, as well as this study
show that ceramide’s ability to induce apoptosis is concentration dependent and cell type
specific. HepG2 cells were also examined before and after MC and sphingolipid
treatments and these cells showed no morphological changes that would indicate cell
death.
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A second theory is the formation ofmembrane rafts or microdomians at the cell
surface. It was first discovered by Huang et al. 1999, using magnetic resonance
spectroscopy that ceramides aggregate into distinct ceramide rich-domains in the plasma
membrane. Veiga et al. 1999 also observed ceramide partitioning into distinct domains
instead of interacting with phospholipids in the plasma membrane. Since these
discoveries many researchers have identified that ceramide-rich raft formation can be
stimulated by CD95, CD4, ionizing radiation, ultra-violet light, heat, bacterial or viral
infection (Cremesti, Goni, and Kolesnick 2002; Gulbins and Kolesnick 2003; Shin, Gao,
and Abraham 2000). These ceramide rich- rafts are capable ofmigrating toward the
center of the cell or can simply remain near the cell surface (Shin, Gao, and Abraham
2000). The formation of these rafts is due to the amphipathic nature of ceramides, their
higher melting temperature, hydrophobicity, and the long fatty acyl chains. These
sphingolipids can undergo tight packing in cell membranes compared to phosopholipids.
Van der Waals forces and hydrogen bonding are responsible for ceramide’s self¬
aggregation into microdomains not seen with other raft forming lipids like cholesterol
(Goni 2005; Liu 1999). This aggregation helps promote and stabilize raft formation.
Cholesterol by itself is incapable of self-aggregating. The experimental results outlined
in this dissertation point toward this theory as an explanation of ceramide and
dihydroceramide’s role in the stimulation of CYPlAl by MC. Not only did MC in the
presence of ceramide increase the production of cytochrome P450, dihydroceramide had
a similar effect on CYPlAl enzyme activity and as well as protein amounts in HepG2
cells. Based on these observations it seems that dihydroceramide is capable of
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modulating CYPl A1 expression by modulating MC’s influx. This however is not
supported by other studies.
Methyl-P-cylcodextrin has been used in numerous experiments to study
cholesterol relevance in the plasma membrane. It was indirectly discovered that this
inhibitor could be used to sequester ceramide. This sequestering is due to the free
hydroxy groups present at the one and four position in ceramide and dihydroceramide’s
chemical structure compared to only one free hydroxyl group in cholesterol’s chemical
structure. Although the experiments outlined in this study did not directly isolate these
rafts, it was did concluded that ceramide ability to form rafts is a very rapid process that
occurs within seconds after MC treatment, rendering it difficult to study MC and
microdomain interactions in the membrane. Other studies using lipid analogs concluded
that raft formation occurred within 13 milliseconds and that the average lifetime of stable
rafts is on the scale of tens of seconds (Dietrich et al. 2002; Schutz et al. 2000; Vereb et
al. 2003).
One last possible explanation for the increased transcription ofCYPlAl in the
presence ofMC and the sphingolipids is based on the characteristics of the plasma
membrane. The plasma membrane contains a mixture of phospholipids, cholesterol, and
sphingolipids. It behaves as a two dimensional fluid mosaic that is crucial for membrane
function. One major function of the plasma membrane of epithelial cells is to ensure that
there is a boundary between different extracellular compartments as a result these cell
types exhibit cell surface polarity. The polarity ofHepG2 cells depends on the structural
asymmetry of the apical and basolateral plasma membrane (Zegers and Hoekstra 1998).
These characteristics are very important to membrane permeability. Studies have shown
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that alterations in ceramide concentration could create small gel domains in cell
membranes, thus changing cell permeability, which can activate membrane-associated
enzymes (Edidin 2003). Other studies indicate an elevated level of sphinganine, a
ceramide precursor, effectively disrupts the plasma membrane domains in well-
differentiated HepG2 cells (van Izendoom et al. 2004). It has been suggested that a
balance among plasma membrane lipids is important in regulating endocytosis (Sharma
et al. 2004). Endocytosis is the incorporation ofmaterials from the outside of the cell by
the formation of vesicles in the plasma membrane. The vesicles surround the material so
the cell can engulf it. There are several types of ligands that can enter through the
endocydic route these can include toxins, growth hormones, viruses, serum transport
proteins and antibodies. Ligands can be brought to the plasma membrane by vesicles
from the trans region of the Golgi complex. The Golgi complex maintains the fluidity of
the membrane so the ligands can move laterally within the membrane and the ligands
aggregate in specialized regions called clathrin coated pits. These cage-like molecules
help stabilize the vesicle as it buds from the membrane. Once the vesicle has formed, the
clathrin coat is lost. After the coat is lost, the vesicles join with other vesicles to form
endosomes or receptosomes. The results in this study suggest that MC may be
endocytosed by the cell through invaginations created by dihydroceramide and ceramide.
Once engulfed, MC and the AhR cytoplasmic complex are rapidly transported to the
Golgi Apartus processed, then translocated to the nucleus. When HepG2 cells are treated
with C6-NDB-ceramide alone, the sphingolipid localized to the Golgi appartus. When
HepG2 cells were treated with MC and C6-NDB-ceramide both compounds localize in
the same compartment in the peri-nuclear region of the cell (Figs. 21 and 22). This
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evidence suggests sphingolipids may assist MC to the Golgi for processing. Once
processed MC and AhR are rapidly translocated to the nucleus, where the increased
transcription ofCYPlA1 is initiated. The increased influx of environmental carcinogens
leads to the increased transcription of the CYPlA1 gene, which can generate derivatives
that may lead to genetic mutations.
This study shows that ceramide and dihydroceramide significantly increased
MC’s ability to induce CYPlA1. It also shows that the mechanism for this effect
increased plasma membrane penetration by MC. This is significant because polycyclic
aromatic hydrocarbons can influence the amount of ceramide generated in the plasma
membrane. Until now dihydroceramides have not been shown to play significant role in
cell growth, differentiation, or apoptosis. This study uncovers yet another role for
ceramides and an active role for dihydroceramides in the biotransformation of potentially
carcinogenic environmental pollutants. The experimental results obtained in this
dissertation clearly demonstrate dihydroceramides are involved in the induction of
CYPlA1 when HepG2 cells are exposed to MC. The results discussed in this dissertation
also allow us to propose a mechanism by which sphingolipids act in this process (Fig.
21). Cells exposed to MC or other PAHs can initiate the production of dihydroceramide
and ceramide through the de novo synthesis pathway or ceramide by the hydrolysis of
sphingomyelin. Once produced these sphingolipids may create invaginations in the
membrane, which could lead to an increased influx ofMC, followed by a rapid
translocation to the nucleus, which would lead to an increased transcription of the
CYPlAl gene.
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Fig. 33. Proposed Model ofCYPl A1 Induction by MC, Ceramide, and Dihydroceramide
through the AhR pathway. Sphingolipids increase MC’s influx in HepG2 cells.
Y = AhR, YY =Amt, CYPlAl =0, Hsp 90 =•, AIP = #, MC =# and Ceramide or
Dihydroceramide =#.
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In conclusion this study has shown that dihydroceramide and ceramide
stimulate the increased production CYPlA1 by MC. These sphingolipids stimulate
CYPlA1 enzyme activity as well as protein amounts. For many years, sphingolipids
were thought inert structural components of the plasma membrane. However,
sphingolipids are a family ofmembrane lipids with important structural roles in the
regulation ofpermeability and sub-domain structure of the lipid bilayer (Edidin 2003; van
Izendoom et al. 2004). The results from this study confirmed that ceramide and
dihydroceramide increase the influx ofMC and that these sphingolipids and MC localize
around the peri-nuclear region ofHepG2 cells. This increased influx ofMC causes the
increased transcription ofCYPIAI. The increased metabolism ofMC by elevated
CYPlAl to electrophiles increases the occurrence of genetic mutations (Baan et al.
1994). Genetic mutations, if not repaired, often lead to cancer. Thus, it is apparent that
other factors besides exposure to polycyclic aromatic hydrocarbons play a role in the
biotransformation of carcinogenic compounds.
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